Volume | 381,542 |
|
|||||
News | (1) | ||||||
Day High | 74.485 | Low High |
|||||
Day Low | 72.34 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CONMED Corporation | CNMD | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
74.48 | 72.34 | 74.485 | 73.09 | 74.98 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,014 | 381,542 | $ 73.32 | $ 27,974,989 | - | 61.05 - 138.47 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 64,003 | $ 73.09 | USD |
CONMED Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.12B | 30.78M | - | 1.24B | 64.46M | 2.09 | 48.43 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
CONMED News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CNMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 74.50 | 76.41 | 72.34 | 75.12 | 464,196 | -1.41 | -1.89% |
1 Month | 63.37 | 76.41 | 61.05 | 69.10 | 622,152 | 9.72 | 15.34% |
3 Months | 80.64 | 86.96 | 61.05 | 74.02 | 538,639 | -7.55 | -9.36% |
6 Months | 108.31 | 117.27 | 61.05 | 85.14 | 521,412 | -35.22 | -32.52% |
1 Year | 119.20 | 138.47 | 61.05 | 96.97 | 445,150 | -46.11 | -38.68% |
3 Years | 139.15 | 159.11 | 61.05 | 105.33 | 368,568 | -66.06 | -47.47% |
5 Years | 100.14 | 159.11 | 37.66 | 100.98 | 358,601 | -27.05 | -27.01% |
CONMED Description
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgery. The firm currently reports through two reporting units, orthopedic surgery (52% of 2018 sales) and general surgery (48%). From a geographic perspective the firm is U.S. centric, with domestic sales accounting for 52% of revenue, EMEA accounting for 19%, APAC at 17%, and the non-U.S. Americas region driving the remaining 12%. |